RU2013153466A - Кристаллическая форма производных индазолиламида для лечения опосредованных глюкокортикоидными рецепторами расстройств - Google Patents
Кристаллическая форма производных индазолиламида для лечения опосредованных глюкокортикоидными рецепторами расстройств Download PDFInfo
- Publication number
- RU2013153466A RU2013153466A RU2013153466/04A RU2013153466A RU2013153466A RU 2013153466 A RU2013153466 A RU 2013153466A RU 2013153466/04 A RU2013153466/04 A RU 2013153466/04A RU 2013153466 A RU2013153466 A RU 2013153466A RU 2013153466 A RU2013153466 A RU 2013153466A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- treatment
- mammal
- medicament
- powder
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 7
- YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical class C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 23
- 241000124008 Mammalia Species 0.000 claims abstract 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 6
- 238000004519 manufacturing process Methods 0.000 claims abstract 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 5
- 230000000241 respiratory effect Effects 0.000 claims abstract 4
- 208000006673 asthma Diseases 0.000 claims abstract 3
- 239000002671 adjuvant Substances 0.000 claims abstract 2
- FCNQMDSJHADDFT-WNSKOXEYSA-N azd5423 Chemical compound COC1=CC=CC([C@@H](OC=2C=C3C=NN(C3=CC=2)C=2C=CC(F)=CC=2)[C@H](C)NC(=O)C(F)(F)F)=C1 FCNQMDSJHADDFT-WNSKOXEYSA-N 0.000 claims abstract 2
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 2
- 230000003448 neutrophilic effect Effects 0.000 claims 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims 1
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 claims 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 claims 1
- 108010067372 Pancreatic elastase Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502656P | 2011-06-29 | 2011-06-29 | |
| US61/502,656 | 2011-06-29 | ||
| PCT/GB2012/051503 WO2013001294A1 (en) | 2011-06-29 | 2012-06-27 | Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013153466A true RU2013153466A (ru) | 2015-08-10 |
Family
ID=46420454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013153466/04A RU2013153466A (ru) | 2011-06-29 | 2012-06-27 | Кристаллическая форма производных индазолиламида для лечения опосредованных глюкокортикоидными рецепторами расстройств |
Country Status (16)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017161518A1 (en) | 2016-03-23 | 2017-09-28 | Astrazeneca Ab | New physical form |
| CN108314670B (zh) * | 2018-02-06 | 2020-04-07 | 江苏八巨药业有限公司 | 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法 |
| EP4253396A4 (en) * | 2020-11-27 | 2024-09-11 | Mirailab Bioscience Inc. | HIGH PURITY BETA-NICOTINAMIDE MONONUCLEOTIDE (NMN) AND PROCESS FOR ITS PRODUCTION |
| CN116283781B (zh) * | 2022-12-16 | 2025-05-13 | 药康众拓(江苏)医药科技有限公司北京分公司 | 一种氘代n-苯基吲唑酰胺类化合物、药物组合物和用途 |
| KR102571432B1 (ko) * | 2023-02-08 | 2023-08-29 | 주식회사 에스씨엘테라퓨틱스 | 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| GB0315509D0 (en) | 2003-07-02 | 2003-08-06 | Meridica Ltd | Dispensing device |
| JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
| WO2008079073A1 (en) | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders |
| KR20130090877A (ko) | 2010-07-21 | 2013-08-14 | 아스트라제네카 아베 | 흡입기 |
| CN103118727B (zh) | 2010-07-21 | 2015-11-25 | 阿斯利康(瑞典)有限公司 | 吸入器 |
-
2012
- 2012-06-27 IN IN23MUN2014 patent/IN2014MN00023A/en unknown
- 2012-06-27 WO PCT/GB2012/051503 patent/WO2013001294A1/en active Application Filing
- 2012-06-27 KR KR1020137033086A patent/KR20140036230A/ko not_active Withdrawn
- 2012-06-27 MX MX2013014566A patent/MX2013014566A/es not_active Application Discontinuation
- 2012-06-27 SG SG2013089966A patent/SG195309A1/en unknown
- 2012-06-27 EP EP12731150.4A patent/EP2726464A1/en not_active Withdrawn
- 2012-06-27 RU RU2013153466/04A patent/RU2013153466A/ru not_active Application Discontinuation
- 2012-06-27 BR BR112013031759A patent/BR112013031759A2/pt not_active IP Right Cessation
- 2012-06-27 CA CA2839398A patent/CA2839398A1/en not_active Abandoned
- 2012-06-27 JP JP2014517935A patent/JP2014527955A/ja active Pending
- 2012-06-27 AU AU2012277514A patent/AU2012277514A1/en not_active Abandoned
- 2012-06-27 CN CN201280039142.8A patent/CN103814015A/zh active Pending
- 2012-06-28 UY UY0001034170A patent/UY34170A/es not_active Application Discontinuation
- 2012-06-28 TW TW101123228A patent/TW201305115A/zh unknown
- 2012-06-29 AR ARP120102359A patent/AR086818A1/es unknown
-
2013
- 2013-12-13 ZA ZA2013/09480A patent/ZA201309480B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG195309A1 (en) | 2013-12-30 |
| AR086818A1 (es) | 2014-01-22 |
| CN103814015A (zh) | 2014-05-21 |
| BR112013031759A2 (pt) | 2016-12-13 |
| UY34170A (es) | 2013-01-31 |
| JP2014527955A (ja) | 2014-10-23 |
| TW201305115A (zh) | 2013-02-01 |
| IN2014MN00023A (enrdf_load_stackoverflow) | 2015-06-12 |
| KR20140036230A (ko) | 2014-03-25 |
| WO2013001294A1 (en) | 2013-01-03 |
| AU2012277514A1 (en) | 2014-01-09 |
| EP2726464A1 (en) | 2014-05-07 |
| MX2013014566A (es) | 2014-09-25 |
| CA2839398A1 (en) | 2013-01-03 |
| ZA201309480B (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006142331A (ru) | Комбинации, содержащие антимускариновые агенты и ингибиторы pde4 | |
| JP2010513478A5 (enrdf_load_stackoverflow) | ||
| RU2013153466A (ru) | Кристаллическая форма производных индазолиламида для лечения опосредованных глюкокортикоидными рецепторами расстройств | |
| NO20045219L (no) | Kalsitonin-gen-relaterte peptid-reseptor-antagonister | |
| MX2010010525A (es) | Inhibidores de metaloproteasa de matriz basados en aril-sulfonamida. | |
| HRP20160071T1 (hr) | Benzodioksinil supstituirani derivati indazola | |
| UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| CO6270360A2 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
| MX2009004289A (es) | Compuestos triciclicos como inhibidores de metaloproteinasas matriciales. | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| CY1108690T1 (el) | Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων | |
| AR060631A1 (es) | Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k) | |
| MY174002A (en) | Combination theraphy for the treatment of diabetes | |
| MX356032B (es) | Compuestos indola y métodos para tratar el dolor visceral. | |
| DK1902026T3 (da) | Tetrahydrocarbazol-derivater, der kan anvendes som androgen-receptor-modulatorer (SARM) | |
| AR067495A1 (es) | Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| UY30906A1 (es) | Productos farmaceuticos comprendiendo primer ingrediente activo n-[2-(dietilamino)-n-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benziotazol-7-il)etil)-3-[2-(1-nafti)etoxi]propanamida o una sal y un segundo seleccionado de un grupo especifico | |
| PE20251690A1 (es) | Compuestos de indazol sustituidos con piperazina como inhibidores de parg | |
| IN2014DN05869A (enrdf_load_stackoverflow) | ||
| DOP2011000055A (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
| AU2020278236B2 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| AR078951A1 (es) | Esferoides de farmacos revestidos y usos de los mismos para la eliminacion o reduccion de afecciones tales como emesis y diarrea | |
| AU2020280272B2 (en) | Methods of treating Chronic Spontaneous Urticaria using a Bruton's tyrosine kinase inhibitor | |
| MX2012007711A (es) | Compuestos de piruvamida como inhibidores de alergeno de peptidasa del grupo 1 de acaros del polvo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150629 |